Servier has partnered with Pieris Pharmaceuticals in a broad immuno-oncology collaboration worth up to EUR1.7 B (US$1.78 B) that includes an upfront payment of EUR30 M (US$31.3 M). Pieris and Servier will primarily develop five bispecific therapeutic programmes, including Pieris’ PRS-332, a PD-1 (programmed cell death receptor-1) checkpoint inhibitor, with the option to expand by up to another three programmes in the future.